Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Current immunotherapies show great promise in cancer clinical trials, but meanwhile posing significant safety risks, i.e. on-target on-tumor, on-target off-tumor, and off-target toxicities. Toxic effects previously reported vary from mild-severe cytokine release syndromes (CRS) to neurotoxicity and death.
A sensitive and reproducible cytotoxicity assay that collectively reflects these functions is an essential requirement for the translation of these cellular therapeutic agents. With advanced technology platforms and extensive expertise, Creative Biolabs is dedicated to developing customized in vitro cytotoxicity analysis services for our global clients.
To study cytotoxicity effects in immunotherapies, several in vitro cytotoxicity assays have been developed. These cell-based assays include colorimetric-based approaches such as MTT and lactate dehydrogenase (LDH) assays, fluorescent-based assays using Calcein AM, luminescent-based assays measuring adenosine triphosphate (ATP) readouts with reagents like CellTiter-Glo, and homogeneous assays using cell lines engineered to express firefly luciferase.
What's more, with the development of multiparameter flow cytometry methods, the measurement of immune-mediated cell killing of tumor cells has become possible. The application of flow cytometry makes it possible to quantify and character both immune effector and tumor cells at the single-cell level. Using different labeling methods (e.g., CellTrace Violet and CFSE), researchers can distinguish effector and target cells by dye labeling, identify live and dead cells by cell viability markers, and characterize the function of the immune cells with multiparameter flow cytometry.
Creative Biolabs has robustly developed in vitro platforms to provide reproducible cell-based cytotoxicity assays for our clients all over the world. We are dedicated to design comprehensive research practices and handle high-quality in vitro studies to support your gene therapy-based I-O products development.
Creative Biolabs'scientists are confident in helping our clients shorten the clinical study journey. We are committed to providing one-stop cytokine release syndrome (CRS) management solutions to reducing the overall project development timeline for our clients. For further details, please don't hesitate to contact us and see how we can help you reach your clinical vision.
References
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
